Cone Health Cancer Center, Greensboro, North Carolina.
Alliance Urology, Greensboro, North Carolina.
Pract Radiat Oncol. 2020 May-Jun;10(3):202-208. doi: 10.1016/j.prro.2020.02.006. Epub 2020 Feb 20.
SpaceOAR hydrogel has been Food and Drug Administration approved to reduce rectal toxicity in prostate radiation therapy. Training and certification for this procedure is performed by the manufacturer, without independent quality measures. We propose a Hydrogel-Implant Quality Score (HIQS) as a surrogate to quantify hydrogel placement accuracy, to assist clinicians in tracking their implant proficiency, and to support quality improvement. A matched-pair study was designed to investigate the benefit of SpaceOAR in rectal dose reduction for low-dose-rate brachytherapy and to validate the principle of the proposed HIQS.
Eighty-one prostate patients were retrospectively selected for this study. Each patient had SpaceOAR implantation under manufacturer supervision. Postprocedure computed tomography and T2-weighted magnetic resonance imaging were acquired for radiation planning. A HIQS system was proposed to evaluate the hydrogel placement quality. Hydrogel implantation was performed immediately after LDR seed placement. For each LDR patient, a non-SpaceOAR patient was matched based upon intraoperative rectal dose and prostate coverage. Intraoperative and postoperative rectal dose reduction was compared between SpaceOAR and non-SpaceOAR groups.
The average HIQS was 77 ± 10.8 (range, 49-97). Rectal anatomic distortions were seen in 17 cases. Significant rectal dose reductions between intraoperative and postoperative plans were found for SpaceOAR patients compared with non-SpaceOAR patients (25.1 Gy vs -5.0 Gy for ΔD and 65.7 Gy vs 13.0 for ΔD). Additional rectal dose reductions (8.4 Gy for ΔD and 12.7 Gy for ΔD) were found for patients without rectal distortion when SpaceOAR was used.
The proposed HIQS system measured the hydrogel placement quality and provided insights into clinician learning and DVH outcome. SpaceOAR was shown to be effective in reducing rectal dose for LDR patients.
SpaceOAR 水凝胶已获得美国食品和药物管理局批准,可降低前列腺放射治疗中的直肠毒性。该手术的培训和认证由制造商进行,没有独立的质量措施。我们提出了一种水凝胶植入物质量评分(HIQS),作为量化水凝胶放置准确性的替代方法,以帮助临床医生跟踪他们的植入技术熟练程度,并支持质量改进。本研究设计了一项配对研究,旨在调查 SpaceOAR 在降低低剂量率近距离放射治疗中直肠剂量方面的益处,并验证拟议的 HIQS 原理。
回顾性选择了 81 例前列腺患者进行本研究。每位患者均在制造商的监督下进行 SpaceOAR 植入。在放射治疗计划中,在术后获得了计算机断层扫描和 T2 加权磁共振成像。提出了 HIQS 系统来评估水凝胶的放置质量。在 LDR 种子放置后立即进行水凝胶植入。对于每个 LDR 患者,根据术中直肠剂量和前列腺覆盖率匹配非 SpaceOAR 患者。比较 SpaceOAR 组和非 SpaceOAR 组之间的术中及术后直肠剂量降低情况。
平均 HIQS 为 77 ± 10.8(范围 49-97)。17 例出现直肠解剖结构扭曲。与非 SpaceOAR 患者相比,SpaceOAR 患者的术中与术后计划之间的直肠剂量显著降低(25.1 Gy 与-5.0 Gy 用于ΔD,65.7 Gy 与 13.0 Gy 用于ΔD)。当使用 SpaceOAR 时,无直肠扭曲的患者还发现了额外的直肠剂量降低(8.4 Gy 用于ΔD 和 12.7 Gy 用于ΔD)。
所提出的 HIQS 系统测量了水凝胶的放置质量,并深入了解了临床医生的学习和剂量体积直方图(DVH)结果。SpaceOAR 被证明可有效降低 LDR 患者的直肠剂量。